First reported 21 hours ago -
Updated 21 hours ago -
On Monday October 6th, the U.S. Court of Appeals for the Federal Circuit will entertain oral argument in another case involving Myriad’s BRCA1
/BRCA2 diagnostic tests. In re BRCA1
- and BRCA2- Based Hereditary Cancer Test Patent Litigation, Case Nos. 14-1361, ...
[Published Lexology - 21 hours ago]